Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs.

Our focus is the metabolic space (e.g. obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics.

Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise.

We work with some of the most interesting and loyal partners and customers from across the world in the pharmaceutical and biotech industry as well as academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.

Biotechnology

Gubra

Henrik Blou

Jacob Tórsheim Voltelen

Niels Vrang

Trine Nygaard Hamann

Kristoffer Rigbolt

Kristian Borbos

Helle Kirstein Erichsen

The Leadership Team at Gubra is responsible for steering the company's strategic direction and ensuring operational excellence. Comprising key executives, such as the CEO, CTO, CFO, COO, and other principal scientists and VPs, the team collaboratively makes high-level decisions, drives scientific innovation, manages business relationships, and upholds the company's commitment to quality and scientific excellence in both its CRO services and proprietary drug discovery programs.

Leadership Team

Research and Scientific Development

Research & Development

Leadership Team

About

Team members

Other teams at Gubra

Research and Scientific Development

Research & Development